Bellerophon Therapeutics, Inc. Common Stock
Own 2 of BLPH at $2.09 which is 0.01% of the portfolio.
|Range Today||$2.32 - $2.45|
|52 Week Range||$0.62 - $2.74|
Bellerophon Therapeutics, Inc. engages in developing products at the intersection of drugs and devices. Its products are using in the treatment of cardiopulmonary and cardiac diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.